DREAMM13
A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function
What's the purpose of the trial?
This is a phase 1 study evaluating the safety, dosage and tolerability of belantamab mafodotin in participants with relapsed or refractory multiple myeloma with both normal and impaired liver function.
Accepting patients
![](https://maps.googleapis.com/maps/api/staticmap?key=AIzaSyDXH19UJTDtS-I9fdYHjFXupEiuQkBgRPk&size=520x280&scale=1&maptype=raodmap&markers=icon%3Ahttps%3A%2F%2Fassets.sparkcures.com%2Fimg%2Fmaps%2Fhospital-default.png%7C41.894501%2C-87.621803%7C34.0667%2C-118.386162%7C40.8839%2C-74.055603%7C32.276699%2C-110.943001%7C40.455299%2C-79.942398%7C33.5723%2C-101.911003%7C42.990923%2C-87.950322%7C32.788101%2C-96.778702%7C39.2882%2C-76.624802%7C36.153613%2C-86.81075%7C30.0851%2C-81.7155%7C37.698182%2C-97.33251%7C41.8605%2C-87.835098)
Participating Centers
There are 13 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Belantamab Mafodotin is an antibody-drug conjugate (ADC) that binds to BCMA on tumor cell surfaces. Belantamab Mafodotin is used in the treatment of multiple myeloma.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Accepting patients
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.